Swipe Left For English News
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，公司荣获2023年“CDMO领军企业奖”，在综合、大型药企、新兴药企三个组别的“能力（Capabilities）”类别评选中脱颖而出。此外，公司还分别在“Accessible Senior Management” 和 “State-of-the-Art”的单项奖评选中超出客户预期。
药明生物全球生物制药开发及运营总裁兼首席技术官
周伟昌博士代表公司领奖
药明生物已经连续六年斩获“CDMO领军企业奖”。公司持续致力于通过前沿技术巩固一体化赋能平台，加快生物药的发现、开发和生产进程。2022年，药明生物支持全球客户获得123个新药临床试验（IND）批准，其中包括一款创新RNA项目。此外，公司在2022年继续扩大能力和规模，位于中国、爱尔兰和美国的生产基地如期投产，全球总产能提升至26.2万升。预计到2026年，药明生物位于中国、美国、爱尔兰、德国以及新加坡的总产能将达到58万升，满足全球客户强劲增长的服务需求。全球供应链网络和多元化布局使公司能够为全球客户提供更加灵活的服务。
陈智胜博士
首席执行官
药明生物
我们很荣幸连续六年获得‘CDMO领军企业奖’。公司取得的优异成绩离不开每一位员工的辛勤努力，更离不开广大客户及合作伙伴对我们的信任与信心。我们将不断加强能力和规模建设，以高质量标准赋能全球合作伙伴加速生物药开发和生产进程，助力其产品早日上市，造福广大病患。
在过去12年中， “CDMO领军企业奖”（前身为“CMO领军企业奖”）由专业杂志Outsourced Pharma和Life Science Leader共同颁发，旨在表彰全球优秀的研发生产服务企业。在2023年的调研中，不同规模的制药企业和生物制药企业受市场调研机构 Industry Standard Research邀请，基于23项指标为其CDMO合作伙伴进行评价，总计覆盖全球72家CDMO公司。
推荐阅读
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物人的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2022年12月底，药明生物帮助客户研发和生产的综合项目高达588个，其中包括17个商业化生产项目。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
媒体关系 PR@wuxibiologics.com
业务垂询 info@wuxibiologics.com
WuXi Biologics Receives CDMO Leadership Awards for Sixth Consecutive Year
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it had received 2023 CDMO Leadership Awards in the "Capabilities" category across all three groups – Overall, Big Pharma and Small Pharma. The company also was recognized for having exceeded customer expectations in the Individual Attribute Awards categories of "Accessible Senior Management" and "State-of-the-Art".
WuXi Biologics won CDMO Leadership Award for the sixth consecutive year. The company has been relentlessly enhancing its integrated enabling platform with leading-edge technologies to expedite biologics discovery, development and manufacturing. In 2022, WuXi Biologics supported its global clients to obtain 123 Investigational New Drug (INDs) approvals, including a novel RNA product. Besides, the company increased its global capacity in 2022 to 262,000L, with new facilities in the U.S., Ireland and China coming online. Total capacity – across five countries – is expected to reach 580,000L by 2026 to meet strong customer demand. Geographic diversity will allow WuXi Biologics to provide more dynamic capabilities to serve its customers anywhere in the world.
Dr. Chris Chen
CEO
WuXi Biologics
We're very pleased to be recognized by the CDMO Leadership Awards for the sixth consecutive year. It speaks to both the trust our global clients have in us and the dedication of our employees. We are committed to enabling our partners in delivering life-saving treatments quickly and effectively to the market, with the aim of benefiting patients worldwide
For the past 12 years, Outsourced Pharma and Life Science Leader have presented the annual CDMO Leadership Awards (previously called the CMO Leadership Awards) based on experiential feedback from sponsor companies. In a survey conducted by Industry Standard Research (ISR) Reports, biopharma customers provide ratings only for CDMOs with whom they have recently worked. For the 2023 CDMO Leadership Awards, 72 global contract manufacturers were evaluated on 23 performance metrics, covering all sizes of companies from both the Pharma and Biopharma industries.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2022, WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
